CClinicalTrials.gg
Not yet recruitingNCT07701668AI-CONECTUpdated Aug 25, 2026

AI-CONECT: A Conversational AI for Early Dementia Prevention in Socially-Isolated Older Adults

An interventional study of AI-based conversational intervention in Mild Cognitive Impairment (MCI) and Social Isolation, sponsored by Massachusetts General Hospital. Not yet recruiting at 1 site in United States. Open to participants aged 75 Years and older. Per ClinicalTrials.gov, last updated 2026-08-25.

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
75 Years and older
Sex
All
01

Study summary

This randomized controlled trial examines the mechanisms of conversational AI-based interventions for early dementia prevention in socially isolated older adults.

Read the detailed description

Social isolation is a well-established and modifiable risk factor for cognitive decline and dementia. The completed I-CONECT trial (NCT02871921) showed that frequent, one-to-one, semi-structured conversational engagement delivered remotely by trained human interviewers improved cognitive outcomes among socially isolated older adults with mild cognitive impairment. Two limitations have constrained translating that approach into a scalable preventive intervention: its reliance on trained human interviewers limits scalability, and the behavioral mechanisms responsible for its cognitive benefits remain incompletely understood.

AI-CONECT addresses both limitations by delivering the conversational intervention through a conversational artificial intelligence (AI) voice chatbot rather than a human interviewer, and by testing a hypothesized behavioral mechanism: that the intervention increases participants' social self-efficacy (confidence in their ability to engage socially), which in turn increases real-world social engagement.

02

Conditions studied

  • Mild Cognitive Impairment (MCI)
  • Social Isolation

Keywords

  • Social Isolation
  • Artificial Intelligence
  • AI-Chatbot
  • I-CONECT
  • Mild Cognitive Impairment (MCI)
03

Who can participate

Ages eligible
75 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Aged 75+
  • Clinical diagnosis of MCI (any subtype) or, when a clinical diagnosis is unavailable, a Telephone-MoCA (T-MoCA) score of 15-17.
  • Identified as socially isolated, defined as meeting both of the following self-reported criteria: (a) lives alone in one's own residence, and (b) engages in conversations lasting 30 minutes or longer no more than twice per week.
  • GDS-15 (15-item Geriatric Depression Scale) at/below 9 (not severely depressed).
  • Social self-efficacy mean ≤ 8 (on the 0-10 scale) across the 6-item Social Self-Efficacy Scale at screening, indicating low confidence in social interaction.
  • Ability to understand the research consent form.
  • Ability to connect a tablet to the Internet.

Exclusion criteria

Exclusion Criteria:

  • Diagnosed with dementia such as AD, ischemic vascular dementia, normal pressure hydrocephalus, or Parkinson's disease.
  • Schizophrenia, or other major psychiatric disorder defined by DSM-IV criteria.
  • Medications: (a) Frequent use of high doses of analgesics; Use of sedative medications except for those used occasionally for sleep (≤2 per week); (b) Use of unstable dosing of Cholinesterase inhibitors (need to be stable dosing for 2 months); (c) AD disease modifying monoclonal antibody treatment e.g., aducanumab or lecanemab (completed the treatment is allowed)
04

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    AI-CONECT

    Participants will receive four 15- to 30-minute conversations per week with the AI agent and a weekly 10- to15-minute survey call with a human interviewer.

    Behavioral: AI-based conversational intervention

  • No intervention
    Control

    Participants will receive a weekly 10- to 15-minute survey call with a human interviewer.

Interventions

  • BehavioralAI-based conversational intervention

    AI-based one-on-one semi-structured conversation for cognitive stimulation

05

What researchers measure

Primary outcomes

  1. Social Self-Efficacy

    Participants' self-efficacy on social interactions using an instrument adapted from the Exercise Self-Efficacy Scale (EXSE, by McAuley, 1993). The scale comprises three items of confidence: interacting with others regularly, engaging with others when feeling less connected, and engaging others in conversations. The three items are adapted to social interaction in person and using technology (e.g., video calls), respectively. Each item is rated from 0 (not at all confident) to 10 (completely confident). A mean score is computed across the six items (range 0-10), with higher scores indicating greater social self-efficacy.

    Time frame: From enrollment to the end of intervention at 8 weeks

  2. Time contacting friends or family

    Change in weekly time contacting friends or family.

    Time frame: From enrollment to the end of the intervention at 8 weeks, using weekly data

Secondary outcomes

  1. Time out of home

    Self-reported weekly time out of home (a proximate measure of social engagement by the participants), using weekly data.

    Time frame: From enrollment to the end of treatment at 8 weeks

  2. Frequency of contacting friends

    Self-reported frequency of contacting friends, using weekly data.

    Time frame: From enrollment to the end of treatment at 8 weeks

Other outcomes

  1. Exploratory outcome: Social isolation score

    Changes in Lubben's social isolation score (6-item version) from baseline to Week 8. The 6-item Lubben Social Network Scale (LSNS-6) is a brief measure of social isolation/social network size and support, particularly in older adults. It includes three questions about family ties and three about friendships, assessing the number of people the individual has contact with, feels close to, and can call on for help. Each item is scored from 0 to 5, giving a total score of 0-30. Higher scores indicate stronger social networks and less social isolation.

    Time frame: From baseline to week 8

  2. Exploratory outcome: Changes in the 3-item UCLA Loneliness Scale (UCLA-3)

    The 3-item UCLA Loneliness Scale (UCLA-3) is a brief measure of perceived loneliness and social disconnection. It asks how often a person feels a lack of companionship, left out, and isolated from others. Each item is scored from 1 (hardly ever) to 3 (often). The total score ranges from 3 to 9, with higher scores indicating greater loneliness.

    Time frame: From baseline to week 8

06

Study locations

1 site
07

References and documents

Individual participant data

Plan to share: Yes — De-identified transcriptions and other collected data may be shared with external researchers under a Data Use Agreement (DUA). Shareable data may include outcome scores, adherence rates, chatbot-usage metrics, full conversational transcripts (after removal of any incidentally disclosed identifiable information), and audio recordings of sessions. Because raw audio recordings may be inherently identifiable, they will be shared only under a DUA. These data may also be made available to the NIH/NIA Program Official upon request. Data are stored on HIPAA-compliant servers (e.g., MGB Business Dropbox and MGB Azure) and encrypted drives. The participant linkage key is kept within Mass General Brigham. No individual-level data are deposited in public or controlled-access repositories under the current protocol; future repository sharing would require additional IRB review and approval.

Supporting information: Analytic code

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07701668
Lead sponsor
Massachusetts General Hospital
Collaborators
Arizona State University
Responsible party
Hiroko Hayama Dodge (Professor, Harvard Medical School, Massachusetts General Hospital) — Principal investigator
First posted
Jul 14, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
May 30, 2028 (estimated)
Completion
Sep 30, 2028 (estimated)
Last update
Aug 25, 2026

Study contacts

Catherine Young
Contact
cyoung@mgh.harvard.edu
617-724-2428
Hiroko H Dodge, PhD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion